News

London, UK, 16 November 2020 – Avvinity Therapeutics Limited (“Avvinity”), an immuno-oncology company developing Alphamer® immunotherapies for solid and haematological cancers, today announces the appointments of Nick Staples as interim CEO and Jon Moore as Non-Executive Director.

Mel Glossop, Avvinity’s Head of Chemistry, presented at the Immuno-Oncology Summit, Europe 2020.

LifeArc, an independent medical research charity, announces a £3.0m co-investment in British biotech Avvinity Therapeutics.

Dr Chris Pickford, Avvinity’s Chief Scientific Officer, presented at the 2020 ELRIG webinar “Next Generation Biologics and the Future of Cancer Therapy” recently.